CereMark Pharma
  • Home
  • Pipeline
    • Overview
    • F-18 Flornaptitril
  • Leadership Team
    • Management Team
    • Board of Directors
    • Emeritus Founders Advisory Board
    • Medical And Science Advisory Board (MSAB)
  • News
  • Contact Us
Select Page

Patent Awarded for PET Radiopharmaceutical for Neurodegeneration Imaging

by Dennis Smith | Oct 7, 2023 | News

CereMark clinical research studies show that Flornaptitril binds with both tau aggregates and beta amyloid plaque in the brain to enhance PET scan imaging. The distribution patterns of these pathological proteins are significant in both Chronic Traumatic...

Hello world!

by Dennis Smith | Sep 25, 2023 | Uncategorized

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Next Entries »

Recent Posts

  • BMJ report highlights CTE in deceased NFL players (2016-2021) – at least one in four
  • CereMark Pharma Begins Phase III Trial of F-18 Flornaptitril, a Novel Diagnostic Radiopharmaceutical Focused on Neurodegeneration  
  • CereMark Pharma and Hall of Fame Health Team Up to Investigate the Clinical Progression of Neurodegeneration in Athletes and Soldiers
  • CereMark Pharma and Invicro to Collaborate on the Development of F-18 Flornaptitril
  • CereMark Pharma Announces New Patents on Selective Imaging Agent of Alzheimer’s Disease, Chronic Traumatic Encephalopathy and Other Neurodegenerative Diseases

Recent Comments

  1. A WordPress Commenter on Hello world!

Contact Us

  • Follow
  • Follow

Our Partners